Literature DB >> 17095156

Detection of circulating antibodies against tau protein in its unphosphorylated and in its neurofibrillary tangles-related phosphorylated state in Alzheimer's disease and healthy subjects.

Hanna Rosenmann1, Zeev Meiner, Valeria Geylis, Oded Abramsky, Michael Steinitz.   

Abstract

While the presence of naturally occurring antibodies (Abs) against amyloid-beta in AD patients and healthy subjects have been repeatedly reported, no data on the presence of naturally occurring Abs against tau protein, in its unphosphorylated as well as its pathologically phosphorylated state, has been reported so far. We describe here the detection of circulating Abs against unphosphorylated and pathologically phosphorylated tau protein in sera of 17 aged subjects: nine Alzheimer's disease (AD) patients and eight healthy individuals. An ongoing autoimmune process may take place, as is suggested by the presence of both IgM class anti-tau Abs, as well as IgG. A preliminary evidence for higher anti-phosphorylated-tau Abs of IgM class in AD patients relative to controls is indicated, but demands further confirmation in a larger sample. Detection of naturally occurring anti-tau antibodies may point to the possibility that some autoimmune process may take place against the tau neuronal protein, including its pathologically phosphorylated state which compose the neurofibrillary tangles. Whether these Abs are neuroprotective or neurotoxic - is unknown, as it is with anti-amyloid-beta Abs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17095156     DOI: 10.1016/j.neulet.2006.01.072

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  26 in total

1.  Recent advances in the development of immunotherapies for tauopathies.

Authors:  Kiren Ubhi; Eliezer Masliah
Journal:  Exp Neurol       Date:  2010-10-21       Impact factor: 5.330

2.  Autoimmune responses to brain following stroke.

Authors:  Kyra Becker
Journal:  Transl Stroke Res       Date:  2012-04-05       Impact factor: 6.829

3.  Autoimmune manifestations in the 3xTg-AD model of Alzheimer's disease.

Authors:  Monica Marchese; David Cowan; Elizabeth Head; Donglai Ma; Khalil Karimi; Vanessa Ashthorpe; Minesh Kapadia; Hui Zhao; Paulina Davis; Boris Sakic
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

4.  Naturally Occurring Antibodies to Tau Exists in Human Blood and Are Not Changed in Alzheimer's Disease.

Authors:  Zhong-Yuan Yu; Wei-Wei Li; Hai-Mei Yang; Noralyn B Mañucat-Tan; Jun Wang; Ye-Ran Wang; Bin-Lu Sun; Zi-Cheng Hu; Li-Li Zhang; Liang Tan; Juan Deng; Yu-Hui Liu
Journal:  Neurotox Res       Date:  2020-02-05       Impact factor: 3.911

5.  Tau is reduced in AD plasma and validation of employed ELISA methods.

Authors:  D Larry Sparks; Richard J Kryscio; Marwan N Sabbagh; Chuck Ziolkowski; Yushun Lin; Lisa M Sparks; Carolyn Liebsack; Sherry Johnson-Traver
Journal:  Am J Neurodegener Dis       Date:  2012-05-15

6.  Antibodies to potato virus Y bind the amyloid beta peptide: immunohistochemical and NMR studies.

Authors:  Robert P Friedland; Johnathan M Tedesco; Andrea C Wilson; Craig S Atwood; Mark A Smith; George Perry; Michael G Zagorski
Journal:  J Biol Chem       Date:  2008-05-27       Impact factor: 5.157

Review 7.  Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence.

Authors:  Richard Dodel; Frauke Neff; Carmen Noelker; Refik Pul; Yansheng Du; Michael Bacher; Wolfgang Oertel
Journal:  Drugs       Date:  2010-03-26       Impact factor: 9.546

8.  Avidity of anti-neurocytoskeletal antibodies in cerebrospinal fluid and serum.

Authors:  L Fialová; J Švarcová; A Bartos; I Malbohan
Journal:  Folia Microbiol (Praha)       Date:  2012-05-08       Impact factor: 2.099

9.  Tau pathology: predictive diagnostics, targeted preventive and personalized medicine and application of advanced research in medical practice.

Authors:  Illana Gozes
Journal:  EPMA J       Date:  2010-06-12       Impact factor: 6.543

Review 10.  Recent advances in tau-directed immunotherapy against Alzheimer's disease: an overview of pre-clinical and clinical development.

Authors:  Pei Ying Ng; I Shuen Chang; Rhun Yian Koh; Soi Moi Chye
Journal:  Metab Brain Dis       Date:  2020-07-06       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.